Global talks have begun on drafting new health rules for combating pandemics, and developing nations are lobbying for fairer access to treatments than they got during COVID-19. But they worry that the odds of a favourable outcome from a scheduled 18 months of negotiations at the World Health Organization (WHO) are already stacked against them, as they lack the negotiating firepower of wealthier countries.
If you are not happy with the results below please do another search
50 search results for:
Findings from Prometheus Biosciences’ Phase II ARTEMIS-UC and Phase IIa APOLLO-CD trials show that PRA023, an anti-TL1A monoclonal antibody, is potentially safe and effective in ulcerative colitis and Crohn’s disease.
Novartis’ Kisqali, combined with endocrine therapy, offered almost a year of progression-free survival (PFS) for an aggressive form of HER+/HER2- metastatic breast cancer, the company announced Tuesday.
Apogee Therapeutics sprang onto the immunology/inflammatory scene Wednesday heavy on capital but light on salient pipeline details.
Boston biopharma Karuna Therapeutics appointed Bill Meury as its new president and chief executive officer, succeeding its current head, Steve Paul, the company announced Tuesday. Meury starts on Jan. 3, 2023.
The deal strengthens the agency’s consumer expertise within healthcare and pharma.
Evolution Road will become part of Inizio’s MarComms business unit, Evoke, enhancing its commercial innovation offering, digital health solutions, and end-to-end omnichannel suite of services.
E-cigarette maker Juul Labs on Tuesday said it has reached settlements with about 10,000 plaintiffs covering more than 5,000 cases in California
Shares of GSK and Sanofi surged on Wednesday, adding more than $20 billion in combined value in early trade following the dismissal of thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer.
Pfizer Inc. said on Wednesday the U.S. Food and Drug Administration will review its respiratory syncytial virus (RSV) vaccine candidate on priority.